Alzheimer's Disease Research Center (ADRC)
Alzheimer’s Disease Treatment Special Notice
On September 27, 2022, the overall results of the large global phase 3 trial of lecanemab were released. This trial was carried out at sites throughout the Unites States and globally, in patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease). This drug is delivered intravenously and removes Alzheimer’s plaques from the brain. The results of this landmark study are significant. Data suggests there is the possibility to slow the progression of Alzheimer’s disease.
This drug, lecanemab, is now being considered for approval by the U.S. Food and Drug Administration. It is not yet approved or available commercially at this time.
Led by some of the best minds in their field, specific projects cover a broad range of scientific disciplines, allowing the Columbia University ADRC to mobilize toward its goals in research and training.
Explore Our Cores
A message from the director of the Alzheimer’s Disease Research Center (ADRC) at Columbia University
As part of its mission, the Columbia University ADRC provides a wide range of resources for investigators to support their efforts
Learn About Our Resources
Interested in Research?
Are you interested in participating in research for the Alzheimer’s Disease Research Center?
Take Our Survey